Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Conditions: Non-small Cell Lung Cancer; IIIb/IIIc/IV; First-line Treatment Interventions: Biological: CIK cell; Biological: IBI308; Drug: Pemetrexed; Drug: Gemcitabine; Drug: Carboplatin Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Hospitals | Immunotherapy | Non-Small Cell Lung Cancer | Research | Study